Printer Friendly

CURATIVE TECHNOLOGIES ANNOUNCES SECOND QUARTER RESULTS

 CURATIVE TECHNOLOGIES ANNOUNCES SECOND QUARTER RESULTS
 EAST SETAUKET, N.Y., Aug. 6 /PRNewswire/ -- Curative Technologies,


Inc. (NASDAQ: CURE) today announced its financial results for the second quarter ended June 30, 1992.
 Total revenues for the quarter increased more than 15 percent to $5.1 million, compared with $4.4 million for the same quarter of 1991. The company recorded a net loss of approximately $2 million, or 21 cents per share for the quarter, vs. a net loss of $.5 million, or 9 cents for the comparable period in 1991.
 Net revenues for the six months of fiscal 1992 were $11.4 million, exceeding revenues of $8.2 million for the first half of 1991 by 39 percent. The net loss for the six months of fiscal 1992 was $2.3 million, or 23 cents per share, compared with a net loss of $1.2 million, or 19 cents per share for the same period last year.
 As previously disclosed, CTI is renegotiating its Wound Care Center agreements to insure continued success assuming the absence of Medicare coverage for Procuren(R). The operating results for the quarter reflect the recording of an estimated allowance against revenue of $1.86 million for the anticipated impact of the complete implementation of restructuring these agreements with all Wound Care Centers(R). "The restructuring process is proceeding as planned, reinforcing CTI's belief that Wound Care Centers can be economically successful for the company and its hospital partners even without Medicare reimbursement," said Gerardo Canet, president of the Wound Care Division. "This restructuring will enable CTI to maintain positive momentum in terms of existing center growth as well as new center development."
 "Although the quarter has been tumultuous, CTI experienced solid growth in the Wound Care Division during the quarter with new patient flow up 11 percent over the first quarter," said Russell B. Whitman, chairman, president and CEO. "Furthermore, the FDA agreement to allow CTI to initiate additional clinical trials in the U.S. for CT-102, the company's homologous platelet derived wound healing formula, constitutes a major step in the development of this product."
 Additionally during the quarter, CTI entered the subacute care market by signing an agreement with Arbor Health Care to provide specialty wound management services to one of Arbor's inpatient centers in Florida. The company also completed the acquisition of UltraMed, Inc., a privately owned company whose principal business is the distribution of wound care supplies and medical equipment. Moreover, CTI received notice of allowance of a broad patent application from the U.S. Patent and Trademark Office, covering both the use of Procuren, the autologous product currently on the market as well as the homologous product which is in the developmental phase.
 Curative Technologies, Inc. is a biopharmaceutical company engaged in the research, development, production and marketing of therapeutic products utilizing naturally occurring human growth factors. The company's first product, Procuren, is a topical therapeutic which promotes wound healing and is produced from a patient's own blood. Procuren is sold through Wound Care Centers, which are cooperative ventures with selected hospitals.
 CURATIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
 Consolidated Statement of Operations
 (Unaudited; dollars in thousands, except per-share data)
 Periods ended June 30 Three Months Six Months
 1992 1991 1992 1991
 Revenue $5,145 $4,457 $11,403 $8,201
 Cost and expenses:
 Cost of product sales 1,189 765 2,327 1,485
 Research and development 1,595 1,153 2,946 2,226
 Marketing, general & admin. 4,645 3,240 9,001 5,882
 Total costs and expenses 7,429 5,158 14,274 9,593
 Loss from operations (2,284) (701) (2,871) (1,392)
 Interested income 229 28 495 62
 Net loss bef. minority interest (2,055) (673) (2,376) (1,330)
 Minority interest in net loss of
 consolidated subsidiary 22 123 58 123
 Net loss (2,033) (550) (2,318) (1,207)
 Net loss per common share $(.21) $(.09) $(.23) $(.19)
 Wtd. avg. com. shrs. outstdg. 9,889 6,357 9,883 6,356
 Consolidated Balance Sheet
 (Unaudited; dollars in thousands)
 6/30/92 12/31/91
 Asset
 Cash and cash equivalents $4,354 $18,919
 Marketable securities 16,480 5,963
 Other current assets 5,520 5,307
 Property and equipment (net) 2,125 1,515
 Other assets 827 755
 Total 29,306 32,459
 Liabilities and stockholders' equity
 Current liabilities 5,042 5,779
 Long-term debt 242 343
 Other liabilities 1,210 1,280
 Stockholders' equity 22,812 25,057
 Total 29,306 32,459
 -0- 8/6/92
 /CONTACT: John C. Prior, CFO of Curative Technologies, 516-689-7000, or Anthony J. Russo or Alexander A. Fudukidis of Noonan/Russo Communications, 212-979-9180, for Curative Technologies/
 (CURE) CO: Curative Technologies, Inc. ST: New York IN: MTC SU: ERN


LD-CK -- NY005 -- 7386 08/06/92 08:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1992
Words:800
Previous Article:VALUE CITY DEPARTMENT STORES ANNOUNCES JULY SALES RESULTS
Next Article:STADTLANDERS SURVEY RANKS TEN MOST ACTIVE ORGAN TRANSPLANT CENTERS
Topics:


Related Articles
CURATIVE TECHNOLOGIES ANNOUNCES FOURTH QUARTER AND YEAR END RESULTS
CURATIVE TECHNOLOGIES ANNOUNCES FOURTH QUARTER AND YEAR END RESULTS
CURATIVE TECHNOLOGIES AND ARBOR HEALTH CARE SIGN AGREEMENT; CURATIVE TECHNOLOGIES TO ENTER SUBACUTE CARE MARKET
CURATIVE TECHNOLOGIES, INC. ANNOUNCES THIRD QUARTER RESULTS
CURATIVE TECHNOLOGIES, INC. ANNOUNCES SECOND QUARTER RESULTS
CURATIVE TECHNOLOGIES, INC. ANNOUNCES SECOND QUARTER RESULTS INCLUDING RESTRUCTURING AND SPECIAL CHARGES
CURATIVE TECHNOLOGIES, INC. ACHIEVES PROFITABILITY IN THE THIRD QUARTER
CURATIVE TECHNOLOGIES, INC. ANNOUNCES SECOND QUARTER RESULTS
Curative Health Services Completes Sale of Procuren(R) Operations.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters